1.29%
-17.37%
-29.91%
-67.56%
-79.95%
-87.92%
-89.25%
AI Spotlight on EVGN
Company Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company.It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform.The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements.
The company operates through three segments: Agriculture, Human Health, and Industrial Applications.The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton.
The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses.The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms.The company also provides medical cannabis products.
It operates in the United States, Israel, Brazil, and internationally.The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd.for the development of novel medical cannabis products.
Evogene Ltd.was founded in 1999 and is headquartered in Rehovot, Israel.
Market Data
| Last Price | 1.57 |
| Change Percentage | 1.29% |
| Open | 1.64 |
| Previous Close | 1.55 |
| Market Cap ( Millions) | 8 |
| Volume | 15513 |
| Year High | 10.4 |
| Year Low | 1.2 |
| M A 50 | 1.59 |
| M A 200 | 3.96 |
Financial Ratios
| FCF Yield | -249.08% |
| Dividend Yield | 0.00% |
| ROE | -493.30% |
| Debt / Equity | -253.42% |
| Net Debt / EBIDTA | 1.52% |
| Price To Book | -18.14 |
| Price Earnings Ratio | -3.35 |
| Price To FCF | -0.4 |
| Price To sales | 1.12 |
| EV / EBITDA | -0.39 |
News
- Nov -21 - Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
- Nov -21 - Evogene Reports Third Quarter 2024 Financial Results
- Nov -20 - EverGen Infrastructure Reports Q3 2024 Results
- Nov -19 - Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
- Nov -13 - EverGen Infrastructure Announces Dates for 2024 Third Quarter Financial Results and Conference Call
- Nov -12 - Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
- Nov -07 - Evogene Schedules Third Quarter 2024 Financial Results Release
- Oct -31 - Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
- Oct -29 - Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
- Oct -08 - Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
- Oct -07 - EverGen Infrastructure Corp. Announces Change of Auditors
- Sep -30 - Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
- Aug -23 - Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
- Aug -22 - Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript
- Aug -22 - EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024
- Aug -22 - Evogene Reports Second Quarter 2024 Financial Results
- Aug -12 - Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- Aug -12 - Evogene Schedules Second Quarter 2024 Financial Results Release
- Jul -31 - Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
- Jul -23 - Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Agriculture
Expected Growth : 9.9 %
What the company do ?
Evogene Ltd.'s Agriculture segment focuses on developing novel traits for crop improvement, enhancing yield, and providing sustainable solutions for the agriculture industry.
Why we expect these perspectives ?
Evogene Ltd.'s 9.9% growth in Agriculture is driven by increasing demand for sustainable crop protection, precision agriculture, and biotechnology solutions. Rising global food security concerns, advancements in gene editing, and growing adoption of digital farming practices also contribute to this growth.
Segment n°2 -> Industrial Applications
Expected Growth : 10.98 %
What the company do ?
Evogene Ltd.'s industrial applications involve developing microorganisms for biofuel, animal feed, and other industrial uses, leveraging its microbial genome editing capabilities.
Why we expect these perspectives ?
Evogene's Industrial Applications segment growth of 10.98% is driven by increasing demand for sustainable and eco-friendly products, expansion into new markets, and strategic partnerships. The company's proprietary gene editing technology and microbial solutions for industries such as agriculture, oil and gas, and pharmaceuticals are also contributing to growth.
Segment n°3 -> Human Health
Expected Growth : 11.57 %
What the company do ?
Human Health from Evogene Ltd. develops novel microbiome-based therapeutics to address various diseases, focusing on unmet medical needs.
Why we expect these perspectives ?
Evogene's Human Health segment growth of 11.57% is driven by increasing demand for microbiome-based therapies, strategic partnerships, and a strong pipeline of novel candidates. The company's AI-powered discovery platform and expertise in gene editing technologies also contribute to its growth momentum.
Segment n°4 -> Unallocated
Expected Growth : 10.47 %
What the company do ?
Unallocated from Evogene Ltd. refers to the remaining shares or funds not assigned to specific projects or initiatives, held by Evogene Ltd. for future use or investments.
Why we expect these perspectives ?
Evogene's 10.47% growth is driven by increasing adoption of its gene editing technology in agriculture, strong partnerships with leading biotech companies, and expansion into new markets such as medical cannabis. Additionally, the company's focus on R&D and intellectual property development has led to a strong pipeline of innovative products, contributing to its rapid growth.
Evogene Ltd. Products
| Product Range | What is it ? |
|---|---|
| Biomarkers | Evogene's biomarkers are genetic markers that can identify specific traits or characteristics in plants, allowing for more efficient and effective breeding. |
| Gene Editing | Evogene's gene editing technology enables precise and efficient modification of genes in plants, allowing for improved traits and characteristics. |
| Microbiome Modulation | Evogene's microbiome modulation technology enables the manipulation of microbial communities to improve plant health and productivity. |
| Crop Design | Evogene's crop design technology uses AI-powered genomics and machine learning to design and develop new crop varieties with improved traits. |
| Gene Discovery | Evogene's gene discovery technology uses advanced genomics and machine learning to identify novel genes and genetic variations. |
| Trait Optimization | Evogene's trait optimization technology uses machine learning and genomics to optimize crop traits for improved performance. |
Evogene Ltd.'s Porter Forces
Threat Of Substitutes
Evogene Ltd. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotech industry.
Bargaining Power Of Customers
Evogene Ltd.'s customers are primarily large corporations and research institutions, which have limited bargaining power due to the specialized nature of the company's products and services.
Bargaining Power Of Suppliers
Evogene Ltd. relies on a limited number of suppliers for its research and development activities, which gives them some bargaining power, but the company's specialized requirements limit the suppliers' negotiating power.
Threat Of New Entrants
The biotech industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Evogene Ltd.
Intensity Of Rivalry
The biotech industry is highly competitive, with many established players and new entrants vying for market share, which increases the intensity of rivalry for Evogene Ltd.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 48.84% |
| Debt Cost | 9.76% |
| Equity Weight | 51.16% |
| Equity Cost | 9.76% |
| WACC | 9.76% |
| Leverage | 95.46% |
Evogene Ltd. : Quality Control
Evogene Ltd. passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| PHARM.AS | Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, … |
| AFMD | Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has … |
| PRTA | Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an … |
| SLGL | Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
Evogene
A-Score
1-Year Total Return ->
🥉
Sol-Gel Technologies
A-Score
1-Year Total Return ->
4
Pharming
A-Score
1-Year Total Return ->
5
Prothena
A-Score
1-Year Total Return ->
6
